- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Eye on Pharma: Daewoong Launches Samsung Bioepis' Trastuzumab Biosimilar
The trastuzumab biosimilar is priced 29.5% below the list price for the trastuzumab reference product, Herceptin.
According to Korean news media, Daewoong Pharmaceutical, a Korean-based bioengineering company, announced yesterday that it has launched a trastuzumab biosimilar the Republic of Korea, sold as Samfenet. Daewoong secured exclusive sales rights for the biosimilar from drug developer, Samsung Bioepis in December 2017.
The trastuzumab biosimilar is priced 29.5% below the list price for the trastuzumab reference product, Herceptin, owned by Roche subsidiary Genentech. In 2016, Herceptin was the world’s eighth best-selling drug, with global sales of $6.7 billion. With the addition of Samfenet, Daewoong strengthens its oncology product portfolio that currently includes a chronic myeloid leukemia treatment, Supect (radotinib), and a prostate cancer drug, Luphere Depot (leuprolide acetate).
Samfenet will not be the only trastuzumab biosimilar available in the Korean market, as Celltrion launched its own biosimilar molecule, Herzuma, in September 2017. At the time of the first biosimilar’s launch, the list price of the originator Herceptin dropped to 70% of its original price, as is the case automatically after all first biosimilar market entries in the Republic of Korea.
In addition to the Korean market, Samsung Bioepis has its eyes on both the European and United States markets for the biosimilar. In December 2017, Bioepis announced that the FDA accepted its Biologics License Application (BLA) for review. If approved, the drug will be commercialized in the United States by Merck, and would compete not only the reference product, but also with Ogivri, Mylan-Biocon’s recently FDA-approved biosimilar trastuzumab (though Ogivri has yet to be launched, and no date for its launch has been publicized).
In the European Union, in November 2017, the European Commission granted Samsung Bioepis a marketing authorization for the biosimilar, making it the first trastuzumab biosimilar approved in that marketplace. Within both the EU and the European Economic Area member states of Norway, Iceland, and Liechtenstein, the drug will be sold as Ontruzant.
Bioepis also reports a number of other biosimilar products included in its pipeline. The company is currently in the midst of developing the following: SB4, etanercept (referecend on Enbrel); SB2, infliximab (referenced on Remicade); SB5, adalimumab (referenced on Humira); SB9, insulin glargine (referenced on Lantus); and SB8, bevacizumab (referenced on Avastin).
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
